The follow-up study, which will enroll patients who had asymptomatic or symptomatic COVID-19 during pregnancy, will assess patients’ symptoms periodically throughout the four-year period and evaluate their offspring for neurologic symptoms and cardiovascular conditions, according to a Nov. 2 news release.
The research team — led by Torri Metz, MD, associate professor of obstetrics and gynecology at the University of Utah School of Medicine in Salt Lake City — will seek to determine what proportion of pregnant people with COVID-19 are at risk for long-term effects and whether illness severity affects the likelihood of developing long COVID-19.
It’s part of the NIH’s larger project to evaluate long COVID-19, known as the Researching COVID to Enhance Recovery, or RECOVER, Initiative.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
